Development and validation of a multivariable prognostic model in de novo metastatic castrate sensitive prostate cancer.

A prognostic model for men with de novo mCSPC was developed and validated in an independent testing set. Our model had high accuracy for predicting OS and rPFS. The model includes commonly used clinical and laboratory parameters and can guide risk stratification of these patients for participation in future trials.